505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Termination of At-The-Market Offering Agreement with R.F. Lafferty
Regains Compliance with Nasdaq Listing Requirements
Announces Closing of $11.0 Million Private Placement
Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
Artelo Biosciences Enters into $337,300 Securities Purchase Agreements
Reports on Financial Statements and Going Concern Matter
Announces Reverse Stock Split
Equity Purchase Agreement with Square Gate Capital for $25 Million
Q1
FY 2024
Q3
Q2
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
S-1
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence